Results 121 to 130 of about 1,579,866 (269)
Enhanced magnetic moment discrimination for multiplex nanoparticle quantification via dual-frequency nonlinearity probing. [PDF]
Bikulov TI +3 more
europepmc +1 more source
ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec +6 more
wiley +1 more source
Reassessing magnetic tunnel junction detectability for ultrasensitive sensing using small-field sensitivity and Jiles-Atherton modeling. [PDF]
Brown BJ, Mitchell LK, Yu H, Xiao G.
europepmc +1 more source
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan +5 more
wiley +1 more source
Realization of room-temperature magnetism and multistep magnetization switching in 2D metallic ferrimagnets. [PDF]
Zhao Z +12 more
europepmc +1 more source
ABSTRACT Background and Purpose White matter hyperintensities (WMH) are a core neuroimaging marker of cerebral small vessel disease (CSVD). Sleep apnoea (SA) is a recognized vascular risk factor, but its associations with regional WMH burden, short‐interval WMH change and cognitive performance in population‐based cohorts remain incompletely defined. We
Peng Cheng +4 more
wiley +1 more source
A Weak-Magnetic-Field Measurement System with Large-Scale Uniformity and a Low Limit of Detection. [PDF]
Meng Q +7 more
europepmc +1 more source
Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket +14 more
wiley +1 more source
Magnetic Composites for Advanced Characterization of Magnetic Field Sensors and Biosensors. [PDF]
Burban EA +7 more
europepmc +1 more source
Magnetism and Some Interesting Magnets* [PDF]
openaire +2 more sources

